Dr Martens surges 23% as investors lace up for recovery story

Dr. Martens shares surged 23% after a better-than-expected full-year update, with adjusted pre-tax profits of £34.1 million, exceeding consensus estimates. The company's net debt decreased to £94.1 million due to a £70 million inventory reduction, and wholesale stock levels have normalized. While revenue declined 10% to £788 million, the autumn/winter 2025 order book shows growth in Europe and the Middle East, with the US stabilizing, leading to optimism about future growth and a strategic shift towards product and consumer engagement.

Analysis

Dr. Martens PLC (LSE:DOCS) experienced a significant 23% share price increase, closing at 74.15p, following a full-year update that surpassed market expectations, suggesting a potential inflection point for the company. Adjusted pre-tax profits for the year to March reached £34.1 million, approximately £2 million ahead of consensus and in line with Peel Hunt’s forecast, despite a 10% year-on-year revenue decline to £788 million. A key positive was the substantial reduction in net debt to £94.1 million, roughly £40 million better than anticipated, driven primarily by a £70 million decrease in inventory. This inventory normalization in wholesale channels, coupled with an encouraging autumn/winter 2025 order book showing growth in Europe and the Middle East and stabilization in the US, signals improving operational health. The company has also articulated a strategic pivot towards product and consumer engagement rather than sales channels, aiming to restore mid-to-high teen EBIT margins over time, supported by £25 million in annualised cost savings. While Peel Hunt anticipates a slight easing in FY26 profit forecasts, they view a £58 million base as realistic, indicating growing confidence in the brand's recovery trajectory from what investors may perceive as its nadir.

Key Decisions for Investors

• Investors may interpret the better-than-expected profit, significant debt reduction, and positive order book trends as early indicators of a turnaround, potentially warranting a review of existing positions or consideration for new investment.
• Monitor the execution of the new strategic focus on product and consumer engagement, alongside sustained improvement in order books and inventory management, as key metrics for validating the recovery thesis.
• While the outlook appears more positive, consider the valuation implications of the 23% share price surge and assess whether the current price adequately reflects both the recovery potential and the ongoing challenges implied by the 10% revenue decline and adjusted FY26 profit expectations.